Here at Zacks, we used to have a service called “Follow the Money.” Similar to Insider Trader and how it follows insider buying, FTM used to follow institutional investor announcements. In today’s day ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against the other stocks. Optimistic ...

This month, tempus’s generative AI (genAI) assistant, Tempus One, launched a range of new capabilities for running queries on millions of unstructured documents for research and clinical care.

Tempus recently gained in-network provider status with Blue Cross Blue Shield across multiple states, allowing for the firm's tests to be covered by insurance. One of Tempus’ business objectives ...

As a result, the idea is that Tempus AI will be able to expand its offering into a hereditary cancer test, making Tempus AI a one-stop shop ... in 2025 doesn't come to pass and instead, its ...

He’ll likely exert his sphere of influence to help pass legislation that benefits the ... as a huge tailwind for biotech stocks. That’s one reason why, among many others, we like biotech ...

On January 14, the company unveiled a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, the company’s generative AI-enabled ...

In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ ... annually over a decade. “Britain will be one of the great AI superpowers. We’re going to make the breakthroughs, we’re ...